Press Releases ALK-Abelló A/S

Stocks

ALK B

DK0061802139

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 16:20:00 10/07/2026 BST			5-day change	1st Jan Change
242.60 ^DKK	-0.25%		-0.57%	+6.12%

06-15	ALK Receives UK Approval For EURneffy 1 Mg As The First And Only Needle-Free Adrenaline Treatment For Young Children At Risk Of Anaphylaxis	CI
06-15	UK Regulator OKs Lower Dose of ALK-Abelló's Severe Allergic Reaction Treatment	MT

Press Releases

06-15	ALK Abelló A/S : EURneffy 1 mg approved in the UK as the first and only needle-free adrenaline treatment for young children (aged 4 and older, 15–30 kg) at risk of anaphylaxis	PU
06-11	ALK Abelló A/S : Anaphylaxis management is falling short in 2026 – EAACI data suggest EURneffy, the only needle-free nasal adrenaline spray, could help close the gap	PU
06-04	ALK will present data on real world-use of nasal adrenaline and key learnings from 20 years with SLIT-tablets at EAACI 2026	GL
06-01	Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff	GL
05-29	ALK to present at the Jefferies Global Healthcare Conference in New York	GL
05-04	ALK Abelló A/S : Presentation	PU
05-04	Three-month interim report (Q1) 2026 (unaudited)	GL
05-04	ALK upgrades its full-year outlook	GL
04-28	ALK Abelló A/S : Invitation to the presentation of ALK's first quarter 2026 results on Tuesday, 5 May 2026	PU
04-28	Invitation to the presentation of ALK’s first quarter 2026 results on Tuesday, 5 May 2026	GL
04-20	ALK announces successful outcome of phase 2 trial with its tablet for treatment of peanut allergy demonstrating early onset of efficacy	GL
04-15	Neffy® approved as the first needle-free anaphylaxis treatment of adults and children in Canada	GL
04-08	Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff	GL
04-01	Grant of share-based long-term incentive instruments to members of the Board of Management and key employees	GL
03-31	EURneffy 1 mg approved across the EU as the first and only needle-free adrenaline treatment for young children (≥15 kg) at risk of anaphylaxis	GL
03-26	ALK Abelló A/S : Annual General Meeting 2026 Minutes	PU
03-16	Annual General Meeting in ALK-Abelló A/S held on 16 March 2026	GL
03-04	New data reveals 9 in 10 people prefer EURneffy, a needle-free nasal adrenaline spray, over auto-injectors	GL
02-20	Annual General Meeting in ALK-Abelló A/S on 16 March 2026	GL
02-20	Henriette Mersebach to step down as ALK’s head of R&D	GL
02-20	Annual report 2025: ALK delivers 15% revenue growth and 26% EBIT margin	GL
02-13	Invitation to the presentation of ALK’s annual report 2025 on Friday, 20 February 2026	GL
01-29	ALK receives positive recommendation for EURneffy® 1 mg: A needle-free anaphylaxis treatment for children	GL
01-08	ALK to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco	GL
12-22	ALK – Financial calendar for the 2026 financial year	GL